Psychotropic Polypharmacy and QT Prolonging Medications in Hospitalized Patients
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70107 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Joel Moore und 7 weiteren Autor:innen. Beteiligte Einrichtung: UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Psychotropic Drugs, Polypharmacy, Long QT Syndrome, Mental Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Medikationssicherheit
Abstract (Originalsprache)
It is common for patients with mental illnesses to be prescribed multiple psychotropic medications to effectively manage their conditions. Psychotropic polypharmacy has been shown to potentiate and increase the risks of several adverse effects, including QT prolongation. This study aimed to investigate the prescribing trends of and differences in prescribing of QT‐prolonging medications (QTPMs) at admission and discharge in hospitalized patients. This retrospective observational study utilized inpatient data from three public hospitals between January and December 2019. QTPMs were classified according to the AZCERT classification. QTPMs doses were evaluated by calculating the ratio of prescribed daily dose (PDD) to the defined daily dose (DDD). Subgroup analyses showed significant differences between patient groups on admission and discharge (all p < 0.001). Mean QTPMs decreased significantly between the two time points only in patients admitted to acute medical and geriatric units ( p < 0.001). PDD/DDD ratio for conditional risk QTPMs in acute mental health unit (AMHU) patients was increased at discharge ( p = 0.038). Patients admitted to acute medical and geriatric units were four and eight times more likely to be discharged with one QTPM with known risk in combination with more QTPMs with conditional risk. Logistic regression showed significant relationships with age and total number of regular medicines at admission for those prescribed high‐dose QTPMs at discharge. The findings underscore the necessity for enhanced monitoring of QTPMs in hospitalized patients, particularly for those at higher risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
- Department of Cardiovascular Medicine, Flinders Medical Centre, Bedford Park, South Australia, Australia.
- College of Medicine & Public Health, Flinders University of South Australia, Bedford Park, South Australia, Australia.
- Department of Clinical Pharmacology, The Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Discipline of Pharmacology, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
- Australian Centre for Precision Health, University of South Australia, Adelaide, South Australia, Australia.
ORCID-Profile: Vijayaprakash Suppiah
Zitieren
APA
Moore, J., Singh, I., Au, R. T., Gabb, G., Eng-Frost, J., Hotham, E., Shakib, S., & Suppiah, V. (2025). Psychotropic Polypharmacy and QT Prolonging Medications in Hospitalized Patients. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70107
Vancouver
Moore J, Singh I, Au RT, Gabb G, Eng-Frost J, Hotham E, et al. Psychotropic Polypharmacy and QT Prolonging Medications in Hospitalized Patients. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70107
BibTeX
@article{Moore2025,
author = {Moore, Joel and Singh, Isabella and Au, Ruby Tszwai and Gabb, Genevieve and Eng-Frost, Joanne and Hotham, Elizabeth and Shakib, Sepehr and Suppiah, Vijayaprakash},
title = {Psychotropic Polypharmacy and QT Prolonging Medications in Hospitalized Patients},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70107}
}
EUVIMED